202 related articles for article (PubMed ID: 15072436)
1. Pharmacophore and receptor models for neurokinin receptors.
Poulsen A; Bjørnholm B; Gundertofte K; Pogozheva ID; Liljefors T
J Comput Aided Mol Des; 2003 Nov; 17(11):765-83. PubMed ID: 15072436
[TBL] [Abstract][Full Text] [Related]
2. A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes.
Poulsen A; Liljefors T; Gundertofte K; Bjørnholm B
J Comput Aided Mol Des; 2002 Apr; 16(4):273-86. PubMed ID: 12400857
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of tachykinin receptor selective agonists: insights from structural studies.
Ganjiwale A; Cowsik SM
Mini Rev Med Chem; 2013 Dec; 13(14):2036-46. PubMed ID: 23937231
[TBL] [Abstract][Full Text] [Related]
4. The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Tian Y; Wu LH; Oxender DL; Chung FZ
J Biol Chem; 1996 Aug; 271(34):20250-7. PubMed ID: 8702757
[TBL] [Abstract][Full Text] [Related]
5. Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship.
Severini C; Salvadori S; Guerrini R; Falconieri-Erspamer G; Mignogna G; Erspamer V
Peptides; 2000 Nov; 21(11):1587-95. PubMed ID: 11090912
[TBL] [Abstract][Full Text] [Related]
6. Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum.
Cheng FH; Chan SW; Rudd JA
Neuropeptides; 2008; 42(5-6):671-9. PubMed ID: 18582934
[TBL] [Abstract][Full Text] [Related]
7. 3D-Quantitative structure-activity relationship and docking studies of the tachykinin NK3 receptor.
Geldenhuys WJ; Simmons MA
Bioorg Med Chem Lett; 2011 Dec; 21(24):7405-11. PubMed ID: 22056747
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
9. Identification, localization and receptor characterization of novel mammalian substance P-like peptides.
Kurtz MM; Wang R; Clements MK; Cascieri MA; Austin CP; Cunningham BR; Chicchi GG; Liu Q
Gene; 2002 Aug; 296(1-2):205-12. PubMed ID: 12383518
[TBL] [Abstract][Full Text] [Related]
10. Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat.
Gaudreau GA; Plourde V
Neurosci Lett; 2003 Nov; 351(2):59-62. PubMed ID: 14583381
[TBL] [Abstract][Full Text] [Related]
11. Postnatal development of NK1, NK2, and NK3 neurokinin receptors expression in the rat retina.
Oyamada H; Takatsuji K; Senba E; Mantyh PW; Tohyama M
Brain Res Dev Brain Res; 1999 Oct; 117(1):59-70. PubMed ID: 10536233
[TBL] [Abstract][Full Text] [Related]
12. Tachykinin receptors in the guinea-pig renal pelvis: activation by exogenous and endogenous tachykinins.
Maggi CA; Patacchini R; Eglezos A; Quartara L; Giuliani S; Giachetti A
Br J Pharmacol; 1992 Sep; 107(1):27-33. PubMed ID: 1384907
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system.
Stratowa C; Machat H; Burger E; Himmler A; Schafer R; Spevak W; Weyer U; Wiche-Castanon M; Czernilofsky AP
J Recept Signal Transduct Res; 1995; 15(1-4):617-30. PubMed ID: 8903968
[TBL] [Abstract][Full Text] [Related]
14. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human.
Lecci A; Capriati A; Altamura M; Maggi CA
Auton Neurosci; 2006 Jun; 126-127():232-49. PubMed ID: 16616700
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist-Neurokinin Antagonist Peptidomimetics.
Gadais C; Piekielna-Ciesielska J; De Neve J; Martin C; Janecka A; Ballet S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500841
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites.
Saffroy M; Torrens Y; Glowinski J; Beaujouan JC
Neuroscience; 2003; 116(3):761-73. PubMed ID: 12573718
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.
Gitter BD; Waters DC; Threlkeld PG; Lovelace AM; Matsumoto K; Bruns RF
Eur J Pharmacol; 1995 May; 289(3):439-46. PubMed ID: 7556412
[TBL] [Abstract][Full Text] [Related]
19. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
20. Tachykinins: receptor to effector.
Khawaja AM; Rogers DF
Int J Biochem Cell Biol; 1996 Jul; 28(7):721-38. PubMed ID: 8925404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
